Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

EMEA restrict two quinolone antibiotics

The European Medicines Agency has recommended restrictions for two quinolone antibiotics, moxifloxacin and norfloxacin.

The press release for moxifloxacin recommends that this antibiotic should only be prescribed in the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis and community-acquired pneumonia when other antibiotics cannot be used or have failed. These recommendations are in response to emerging safety concerns about an increased risk of adverse hepatic reactions. A question and answer document contains information for patients and clinicians.

The press release for norfloxacin recommends that the licence for this antibiotic in the treatment of acute or chronic complicated pyelonephritis be withdrawn because the benefits of these medicines do not outweigh their risks in this indication. Usage in other indications is unaffected. A question and answer document contains information for patients and clinicians.

Action: Clinicians should be aware of the recommendations and ensure that use of these antibiotics falls within the new recommendations.

Share 'EMEA restrict two quinolone antibiotics' on Email Share 'EMEA restrict two quinolone antibiotics' on Delicious Share 'EMEA restrict two quinolone antibiotics' on Digg Share 'EMEA restrict two quinolone antibiotics' on Facebook Share 'EMEA restrict two quinolone antibiotics' on Google+ Share 'EMEA restrict two quinolone antibiotics' on reddit Share 'EMEA restrict two quinolone antibiotics' on StumbleUpon Share 'EMEA restrict two quinolone antibiotics' on Twitter

atomic-wealth

No Comments to “EMEA restrict two quinolone antibiotics”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,321 spam comments.

atomic-wealth
fond-illness
summer